|
How A Black-And-White View Of Pharma Companies Blinds Us To Real Problems
Forbes I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me or follow me on Twitter. For many people, small things … |
 Citybizlist |
Executive appointments at Merck & Co, Actelion and Jazz Pharma
The Pharma Letter US drug giant Merck & Co (NYSE: MRK) has appointed Cuong Viet Do as chief strategy officer, effective October 3. In this position he will be responsible for both developing and executing enterprise-wide strategy and further building connections between … Merck goes outside drug industry for strategy exec, (NYSE: MRK), (NYSE: TEL) |
 BBC News |
Merck, Sanofi's Cancer Vaccine Beats Glaxo's Rival on Cost
BusinessWeek Sept. 28 (Bloomberg) — Merck & Co. and Sanofi's cervical- cancer vaccine is more cost-effective than a rival product made by GlaxoSmithKline Plc, researchers from the UK's Health Protection Agency found. … Doubts over cervical cancer jab HPV Vaccines Differ in Cost-Effectiveness and Cancer Deaths Gardasil bests Cervarix in cost effectiveness battle |
 News10.net |
Pfizer, pharmacy group warn on counterfeit drugs
Wall Street Journal AP Pfizer Inc. and a pharmacy standards group are teaming to warn consumers about the risks of counterfeit prescription medicines, which endanger the public and take money from both pharmacies and legitimate drugmakers. Pfizer Inc., whose impotence … Pfizer, pharmacy group warn on counterfeit drugs The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate … Pfizer, pharmacy group warn on counterfeit drugs |
 The Star-Ledger – NJ.com |
J&J acquires Merck's stake in joint venture
BusinessWeek Drugmaker Merck & Co. has sold its interest in a joint venture that makes and sells over-the-counter drugs to Johnson & Johnson for $ 175 million, the companies said Wednesday. The 22-year-old joint venture, Johnson & Johnson-Merck Consumer … Business news in brief | Philadelphia Inquirer | 2011-09-29 J&J Buys Out Merck Share Of Heartburn-Products Joint Venture J&J Buys Merck Out of Partnership |
 CNBC.com |
Novartis Seeks European Marketing Authorization For Lung-Disease Drug Seebri
RTT News (RTTNews) – Japanese biopharmaceutical company Sosei Group Corp. Tuesday announced that Swiss drug maker Novartis AG (NVS: News ) has filed NVA237 for marketing authorization under the brand-name Seebri Breezhaler with the European Medicines Agency, … New Novartis data show potential of respiratory portfolio to help COPD … Novartis's Seebri Improves Lung Function in Smokers, Study Shows Vectura Gets $ 5 Million Milestone As Novartis Files Lung Drug |
|
Elite Pharmaceuticals and ECR Pharmaceuticals Launch Lodrane D(R) Allergy Product
MarketWatch (press release) NORTHVALE, NJ, Sep 27, 2011 (GlobeNewswire via COMTEX) — Elite Pharmaceutical, Inc.'s ("Elite" or the "Company") /quotes/zigman/218918 ELTP -2.60% and ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal (Hi-Tech), … |
 Proactive Investors USA & Canada |
Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland …
MarketWatch (press release) BLUE BELL, Pa., Sept. 27, 2011 /PRNewswire via COMTEX/ — Inovio Pharmaceuticals, Inc. /quotes/zigman/374264/quotes/nls/ino INO -2.63% , a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that … Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland … Inovio Pharmaceuticals Inks Pact With US DHS To Study FMD Vaccine – Quick Facts Inovio Pharmaceuticals Enters Collaboration with US Department of Homeland … |
 Proactive Investors USA & Canada |
Money splice infuses RXi
Worcester Telegram By Lisa Eckelbecker TELEGRAM & GAZETTE STAFF The solution RXi reached gives the RNAi business enough money for two years, said Mark J. Ahn, RXi's chief executive. WORCESTER — RXi Pharmaceuticals Corp. is splitting into two companies infused with a … RXi Pharmaceuticals(R) to Strengthen Strategic Focus by Separating Into Two … RXi Splits Into Two Public Companies After Adding Cancer Vaccine to Pipeline RXi forming two public companies |
|
Novartis cleared to market two drugs in Japan
MarketWatch By Zurich Bureau ZURICH -(MarketWatch)- Novartis AG /quotes/zigman/171707/quotes/nls/nvs NVS +1.57% Tuesday said it has received regulatory approval in Japan for once-daily Gilenya (fingolimod) for the prevention of relapse and delay of progression of … Novartis receives approval in Japan for two innovative therapies, Gilenya® in … Novartis Gets Approval In Japan For Two Innovative Therapies |
